



The NEW ENGLAND JOURNAL of MEDICINE

HOME | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP

Please [sign in](#) for full text and personal services

ORIGINAL ARTICLE

[◀ Previous](#)

Volume 354:251-260

[January 19, 2006](#)

Number 3

[Next ▶](#)

Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV

Joel E. Gallant, M.D., M.P.H., Edwin DeJesus, M.D., José R. Arribas, M.D., Anton L. Pozniak, M.D., Brian Gazzard, M.D., Rafael E. Campo, M.D., Biao Lu, Ph.D., Damian McColl, Ph.D., Steven Chuck, M.D., Jeffrey Enejosa, M.D., John J. Toole, M.D., Ph.D., Andrew K. Cheng, M.D., Ph.D., for the Study 934 Group

ABSTRACT

Background Durable suppression of replication of the human immunodeficiency virus (HIV) depends on the use of potent, well-tolerated antiretroviral regimens to which patients can easily adhere.

Methods We conducted an open-label, noninferiority study involving 517 patients with HIV infection who had not previously received antiretroviral therapy and who were randomly assigned to receive either a regimen of tenofovir disoproxil fumarate (DF), emtricitabine, and efavirenz once daily (tenofovir–emtricitabine group) or a regimen of fixed-dose zidovudine and lamivudine twice daily plus efavirenz once daily (zidovudine–lamivudine group). The primary end point was the proportion of patients without baseline resistance to efavirenz in whom the HIV RNA level was less than 400 copies per milliliter at week 48 of the study.

Results Through week 48, significantly more patients in the tenofovir–emtricitabine group reached and maintained the primary end point of less than 400 copies of HIV RNA per milliliter than did

THIS ARTICLE

- Full Text
- PDF
- PDA Full Text
- PowerPoint Slide Set
- CME Exam
- Translated Abstracts
 - [Deutsch](#)
 - [Español](#)
 - [Français](#)
 - [Italiano](#)

TOOLS & SERVICES

those in the zidovudine–lamivudine group (84 percent vs. 73 percent, respectively; 95 percent confidence interval for the difference, 4 to 19 percent; $P=0.002$). This difference excludes the inferiority of the tenofovir DF, emtricitabine, and efavirenz regimen, indicating a significantly greater response with this regimen. Significant differences were also seen in the proportion of patients with HIV RNA levels of less than 50 copies per milliliter (80 percent in the tenofovir–emtricitabine group vs. 70 percent in the zidovudine–lamivudine group; 95 percent confidence interval for the difference, 2 to 17 percent; $P=0.02$) and in increases in CD4 cell counts (190 vs. 158 cells per cubic millimeter, respectively; 95 percent confidence interval for the difference, 9 to 55; $P=0.002$). More patients in the zidovudine–lamivudine group than in the tenofovir–emtricitabine group had adverse events resulting in discontinuation of the study drugs (9 percent vs. 4 percent, respectively; $P=0.02$). In none of the patients did the K65R mutation develop.

- Add to Personal Archive
- Add to Citation Manager
- Notify a Friend
- E-mail When Cited
- E-mail When Letters Appear

MORE INFORMATION

- Find Similar Articles
- PubMed Citation

Conclusions Through week 48, the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs. (ClinicalTrials.gov number, NCT00112047 [[ClinicalTrials.gov](#)] .)

Source Information

From the Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore (J.E.G.); the Orlando Immunology Center, Orlando, Fla. (E.D.); Hospital de La Paz, Madrid (J.R.A.); Chelsea and Westminster Hospital, London (A.L.P., B.G.); the University of Miami, Miami (R.E.C.); and Gilead Sciences, Foster City, Calif. (B.L., D.M., S. C., J.E., J.J.T., A.K.C.).

Address reprint requests to Dr. Gallant at the Division of Infectious Diseases, Johns Hopkins University School of Medicine, 1830 E. Monument St., Rm. 443, Baltimore, MD 21287, or at jgallant@jhmi.edu .

Full Text of this Article

This article has been cited by other articles:

- Clay, P. G, Dong, B. J, Sorensen, S. J, Tseng, A., Romanelli, F., Antoniou, T. (2006). Advances in Human Immunodeficiency Virus Therapeutics. *Ann Pharmacother* 40: 704-709 [[Abstract](#)] [[Full Text](#)]
- (2006). What's the Optimal Initial ART Regimen for HIV?. *Journal Watch Infectious Diseases* 2006: 2-2 [[Full Text](#)]
- (2006). A Single Pill for AIDS Nears Reality. *jwacc* 2006: 1-1 [[Full Text](#)]

- (2006). A Single Pill for AIDS Nears Reality. *Journal Watch Gastroenterology* 2006: 9-9 [\[Full Text\]](#)
 - (2006). A Single Pill for AIDS Nears Reality. *Journal Watch (General)* 2006: 4-4 [\[Full Text\]](#)
-

HOME | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP

Comments and questions? Please [contact us](#).

The New England Journal of Medicine is owned, published, and [copyrighted](#) © 2006 [Massachusetts Medical Society](#). All rights reserved.